



Herbal medicines for cancer cachexia : Protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005016
Article Type:	Protocol
Date Submitted by the Author:	07-Feb-2014
Complete List of Authors:	Park, Bongki; Korea Institute of Oriental Medicine, Medical Research Division Jun, Ji Hee; Korea Institute of Oriental Medicine, Medical Research Division Jung, Jeeyoun; Korea Institute of Oriental Medicine, Medical Research Division You, Sooseong; Korea Institute of Oriental Medicine, Medical Research Division Lee, Myeong Soo; Korea Institute of Oriental Medicine, Medical Research Division
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Oncology
Keywords:	COMPLEMENTARY MEDICINE, Adult oncology < ONCOLOGY, Herbal medicine < THERAPEUTICS

SCHOLARONE™
Manuscripts

Only

1
2
3
4
5
6
7
8
9

Herbal medicines for cancer cachexia : Protocol for a systematic review

10
11
12
13
14
15
16
17
18
19

Bongki Park, Ji Hee Jun, Jeeyoun Jung, Sooseong You, Myeong Soo Lee

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Running title: Protocol of systematic review of herbal medicine for cancer cachexia

***Correspondence to:**

Myeong Soo Lee, PhD

Medical Research Division,

Korea Institute of Oriental Medicine,

Daejeon, 305-811, South Korea

Tel: 82-(0)42-868-9266

Fax: 82-(0)42-868-9622

E-mail: drmslee@gmail.com

Park BK: sanisapa@kiom.re.kr

Jun JH: zhixi04@kiom.re.kr

Jung JY: jjy0918@kiom.re.kr

You SS: ethink33@kiom.re.kr

Lee MS: drmslee@gmail.com

1
2
3
4 License statement
5

6 *The Corresponding Author has the right to grant on behalf of all authors and does grant on*
7 *behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a*
8 *worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if*
9 *accepted) to be published in BMJ Open and any other BMJ PGL products to exploit all*
10 *subsidiary rights, as set out in our licence ([http://group.bmj.com/products/journals/](http://group.bmj.com/products/journals/instructions-for-authors/licence-forms)*
11 *instructions-for-authors/licence-forms).*
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: To assess the efficacy of herbal medicines as a treatment of cancer cachexia.

Methods and analysis: We will search the following thirteen electronic databases from their inception. MEDLINE (PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Allied and Complementary Medicine Database (AMED), China National Knowledge Infrastructure (CNKI), Wanfang, Journal Integration Platform (VIP) and six Korean Medical Databases (Korean Studies Information, DBPIA, Korea Institute of Science Technology Information, Research Information Center for Health Database, Korean Medline, and National Assembly Library) without restrictions on time or language. The data will be extracted independently by two authors using pre-defined criteria. Disagreements will be resolved by discussion between the authors. The risk of bias will be assessed using the Cochrane of risk of bias tool.

Dissemination: The review will be published in a journal. The review will also be disseminated electronically and in print. An updated of the review will be conducted to inform and guide healthcare practice and policy.

Trial registration number: PROSPERO 2013:CRD42013006612

Keywords: Cancer, cachexia, herbal medicine, traditional East Asian medicine, randomised clinical trials, systematic review

Article focus

- *This systematic review aims to evaluate randomized controlled trials and quasi-randomised trials and to present the efficacy of herbal medicines for cancer cachexia.*

Key messages

- *This systematic review will be performed with a comprehensive search strategy and will establish the current state of the evidence using unbiased methods.*

Strengths and limitations of this study

- *The strength of this review is its extensive, unbiased search of various databases without language restriction.*
- *The trial screening and data extraction will be conducted independently by two authors.*
- *The review team consists of experts from each field: traditional Korean medicine (Park BK, Jung JY), traditional Chinese medicine (Jun JH), conventional medicine (You SS) and methodology (Lee MS).*

Introduction

Description of the condition

Cancer cachexia is a common syndrome among cancer patients, especially in advanced cancer. More than 70~80% of advanced cancer patients suffer from cachexia.¹

Generally, cachexia is characterised by loss of weight, muscle atrophy, anorexia and fatigue.

The definition of cancer cachexia differs slightly according to the research study,²⁻⁵ but the recent international consensus has defined cancer cachexia as a multifactorial syndrome characterised by ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.⁴ The pathophysiology of cancer cachexia is a negative energy balance caused by a variable combination of reduced food intake and abnormal metabolism.^{4 6} The metabolic mechanisms of adipose mass reduction, loss of skeletal muscle and protein degradation are known to be mediated by pro-inflammatory cytokines, neuropeptides, hormones, catabolic factors and digestive factors.^{1 6-8}

Cancer cachexia causes numerous clinical problems. Cancer cachexia reduces activity or quality of life⁹ and restricts conventional therapy such as chemotherapy.¹⁰ Above all, Cancer cachexia is associated with a poor survival rate.^{11 12} In various cancer types, the survival of patients with cachexia is shorter than that of other patients.¹

Description of the intervention

There are several agents for managing cancer cachexia. Megestrol acetate, cannabinoids, corticosteroids and ghrelin are known to affect appetite. EPA, HMB, thalidomide, corticosteroids and non-steroidal anti-inflammatory drugs are known to affect cachectic mediators or signal pathways.^{1 6 13} Some drugs, such as megestrol acetate and corticosteroids exhibit confirmed effectiveness in combatting cancer cachexia by randomised controlled

1
2
3
4 trials and systematic reviews.¹ However, to date, there is no identified standard treatment for
5
6 cancer cachexia.
7

8 Herbal medicines have been used widely to treat diverse diseases for thousands of years.
9
10 Especially in East Asia, herbal medicines have been developed on a basis of unique theories:
11
12 Yin and Yang, the five elements and visceral manifestation theory. The major principle of
13
14 treating diseases is reinforcing the healthy qi and eliminating the pathogenic factors. Many
15
16 herbal medicines are prescribed according to this principle.
17

18
19 Recently, herbal medicines have been used to alleviate the adverse effects of conventional
20
21 therapies or to improve a quality of life. A survey demonstrated that 75% of colorectal cancer
22
23 patients used at least one type of complementary alternative medicine (CAM) during their
24
25 lifetimes.¹⁴ Another survey reported that 39% of breast cancer patients used herbs or medical
26
27 herbal teas.¹⁵
28
29

30 31 32 ***How the intervention might work***

33
34 Some herbs, such as ginseng radix, astragali radix or some herbal prescriptions, are known to
35
36 increase appetite, facilitate physical function and boost immune function.¹⁶⁻²⁰ Other herbs,
37
38 such as coptidis rhizoma, exhibit anti-inflammatory functions.²¹⁻²³ Many herbs are associated
39
40 with anti-cancer properties including cancer cell - cytotoxicity, cell-apoptosis and invasion
41
42 and metastasis prevention.²⁴⁻²⁶
43
44

45
46 Many practitioners and researchers have attempted to explore herbal medicines for the
47
48 treatment of cancer cachexia. The oral administration of Rikkunshito is known to stimulate
49
50 ghrelin secretion.²⁷ One research study reported that coptidis rhizoma might exhibit an anti-
51
52 cachectic effect and that berberine, the major component, might prevent cancer-induced
53
54 cachexia.²⁸
55
56
57
58
59
60

Why it is important to do this review

To our knowledge, no systematic reviews assessing herbal medicines in cancer cachexia have been conducted. There is no identified standard treatment for cancer cachexia, and a comprehensive evaluation of the efficacy and the safety of herbal medicines will inform the recommendation for treatment of cancer cachexia.

Objectives

To assess the efficacy of herbal medicines for cancer cachexia.

Methods

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs) and quasi-randomised trials (quasi-RCTs) will be included in this systematic review without restrictions on time or language.

Types of participants

The participants will include cancer patients diagnosed by histological or clinical diagnosis who meet the international consensus of cancer cachexia⁴. The diagnostic criteria for cancer cachexia are as follows :

1. Weight loss > 5% over the past 6 months (in absence of simple starvation); or
2. Body Mass Index (BMI) < 20 and any degree of weight loss > 2%; or
3. Appendicular skeletal muscle index consistent with sarcopenia (males < 7.26 kg/m; females < 5.45 kg/m) and any degree of weight loss > 2%

Types of interventions

1
2
3
4 All types of herbal medicines will be included. There is no limitation on the number of herbs,
5
6 administration methods, dosage or duration of treatment. The comparisons will be either with
7
8 other therapeutic agents such as megestrol acetate or corticosteroids or with no other
9
10 treatment.
11

12 13 14 15 *Types of outcome measures*

16 17 Primary outcomes

- 18 1. Weight gain.
- 19 2. Body composition.

20 21 22 Secondary outcomes

- 23 1. Improvement in quality of life by means of a validated instrument.
- 24 2. Increase of appetite.
- 25 3. Reduction in fatigue.
- 26 4. Serum levels of inflammatory markers, including ESR and CRP as well as TNF-alpha, IL-
27 1, IL-6, and IFN-gamma.
- 28 5. Adverse effects.

29 30 31 32 33 34 35 36 37 38 39 40 41 *Search methods for the identification of studies*

42 43 Electronic searches

44 We will search the following electronic databases regardless of publication date or language:

- 45 ● MEDLINE (PubMed),
- 46 ● The Cochrane Central Register of Controlled Trials (CENTRAL),
- 47 ● EMBASE,
- 48 ● Allied and Complementary Medicine Database (AMED),
- 49 ● China National Knowledge Infrastructure (CNKI),

- Wanfang Database.
- VIP (Journal Integration Platform)
- Six Korean Medical Databases (Korean Studies Information, DBPIA, Korea Institute of Science Technology Information, Research Information Center for Health Database, Korean Medline, and National Assembly Library)

Other sources

We will scan the reference lists of reviews and retrieve articles for additional studies. In addition, we will search the WHO International Clinical Trials Registry Platform (ICTRP) (<http://apps.who.int/trialsearch/>), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com/mrct), clinical trials.gov ([www. Clinicaltrials.gov](http://www.Clinicaltrials.gov)) and Google scholar (<http://scholar.google.co.kr/>).

Search strategy

We will model subject strategies for databases on the search strategy designed for MEDLINE (PubMed; see Appendix 1) and CNKI (see Appendix 2) and modify it for use in the other databases.

Data collection and analysis

Selection of studies

Two review authors (Park BK and Jun JH) will independently assess the titles and abstracts of articles searched by electronic databases and determine their eligibility for inclusion. Hard copies of the relevant articles will be retrieved. Disagreements will be resolved by discussion, if necessary, by the arbiter (Lee MS).

Data extraction and management

Two review authors (Park BK and Jun JH) will read all the articles and independently extract the data using a standard data extraction form. The form includes methodology, participants, interventions, duration of treatment, outcomes and conclusions. Consensus will be reached by discussion in the case of discrepancy. When disagreements are not resolved by discussion, they will be arbitrated by another author (Lee MS).

Assessment of the risk of bias in the included studies

Three authors (Park BK, You SS and Jung JY) will assess the risk of bias using the Cochrane tool of risk of bias (version 5.1.0).²⁹ The following items will be assessed: random sequence generation (selection bias), allocation concealment (selection bias), blinding (performance bias and detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other bias. The evaluated domains will be assessed as Yes, No or Unclear according to the criteria. We will resolve any disagreements by discussion or arbitration (Lee MS).

Measurement of the treatment effect

We will use the mean difference (MD) with 95% confidence intervals (CI) for continuous outcomes or risk ratios (RR) with 95% CI for binary outcomes. In the case of the use of different measurement scales, standardised mean difference (SMD) analysis with 95% CI will be performed.

Units of analysis issues

We will include data from parallel-group studies for the meta-analysis. If we include cross-over trials, only the first treatment period data will be analysed. When the trial has more than

1
2
3
4 one control group, the unit of analysis will be applied to each group.
5
6
7

8 *Dealing with missing data*

9
10 We will try to contact the corresponding authors by e-mail if there is any missing or
11 insufficient data from the trial as much as possible. The intent-to-treat (ITT) principle will be
12 applied for statistical analysis. The individual patient data will be sought from the original
13 source or from the published trial reports when the individual patient data are unavailable.
14
15
16
17
18
19

20 *Assessment of heterogeneity*

21
22 We will use the random effects model for the meta-analysis. Heterogeneity will be assessed
23 by inspecting the forest plots. In addition, heterogeneity will be tested by the I^2 test for
24 quantifying inconsistencies among the included studies. A result higher than 50% would
25 represent substantial heterogeneity. If heterogeneity exists, we will conduct a subgroup
26 analysis to examine the possible cause.³⁰
27
28
29
30
31
32
33
34
35
36

37 *Assessment of reporting biases*

38
39 If more than 10 trials are included in the meta-analysis, we will conduct funnel plots to assess
40 the potential for publication bias and small study effects.³¹ Asymmetry in funnel plots
41 implied possible small study effects, such as publication bias. We will include all eligible
42 trials, regardless of their methodological quality.
43
44
45
46
47
48
49

50 *Data synthesis*

51
52 If there are sufficient studies and comparable outcomes, we will perform a meta-analysis
53 using random effect modelling.
54
55
56

57 1. Herbal medicine versus conventional medical treatments

1
2
3
4 2. Herbal medicine versus no treatment
5

6 3. Herbal medicine versus placebo
7

8 4. Herbal medicine plus conventional medical treatment versus conventional medical
9 treatment only
10
11

12 *Subgroup analysis and investigation of heterogeneity*

13
14
15
16
17 If there are sufficient data, subgroup analyses will be conducted to explore the differences in
18 the effect sizes, type of cancer, stage of cachexia⁴ and types of herbal medicine.
19
20

21 *Sensitivity analysis*

22
23
24 For sensitivity analysis, the meta-analysis will be repeated, substituting decisions
25 alternatively to test the robustness of the primary decisions of the review process. The
26 principal decision nodes are as follows:
27
28
29

30
31
32
33 1. Methodological quality (sequence generation, allocation concealment or blinding in the
34 assessment of outcomes and symptom severity);
35

36
37 2. Sample size (small sample size studies, e.g., over 30 in each group)
38
39

40 41 **Ethics and dissemination**

42
43
44 Ethical approval is not required, given that this protocol is for a systematic review. The
45 review will be disseminated widely through peer-reviewed publications and conference
46 presentations.
47
48
49

50 51 **Discussion**

52
53
54
55 This is the protocol for a review and there is no primary data collection. The systematic
56 review will be published in a peer-reviewed journal and disseminated electronically or in
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

print. Updates of the review will be conducted to inform and guide healthcare practice and policy.

For peer review only

Contribution of authors

All authors (Park BK, Jun JH, Jung JY, You SS and Lee MS) contributed to the drafting of the protocol. The protocol was revised, and the final version was approved by all authors. The search strategy was developed and will be run by Park BK and Jun JH. Copies of studies will be obtained by Park BK and Jun JH. Selection of the studies to include will be done by Park BK and Jun JH. Lee MS will act as an arbiter in the study selection stage. Extraction of data from studies will be conducted by Park BK, Jun JH, Jung JY and You SS. Entering data into RevMan will be conducted by Park BK, Jung JY. Carrying out the analysis will be done by Park BK, Jung JY and Lee MS. Interpretation of the analysis will be done by all authors. The final review will be drafted by all authors. The review will be updated by Park BK and Lee MS.

Competing interests

None declared

Funding

The authors were supported by Korea Institute of Oriental Medicine (K13400, K13281).

References

1. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. *Crit Rev Oncol Hematol* 2013;**88**:625-36.
2. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. *Clin Nutr* 2008;**27**:793-9.
3. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". *Clin Nutr* 2010;**29**:154-9.
4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011;**12**:489-95.
5. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score. *Cancer treatment reviews*. *Cancer Treat Rev* Published Online First: 28 November 2013. doi: 10.1016/j.ctrv.2013.11.007.
6. Tisdale MJ. Mechanisms of cancer cachexia. *Physiol Rev* 2009;**89**:381-410.
7. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. *Trends Endocrinol Metab* 2013;**24**:174-83.
8. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell Metab* 2012;**16**:153-66.
9. Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. *Lung Cancer* 2003;**40**:295-9.
10. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin Cancer Res* 2009;**15**:2920-6.

- 1
2
3
4 11. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment
5
6 of anorexia-cachexia syndrome. *Cochrane Database Syst Rev* 2013;**3**:CD004310.
7
- 8
9 12. Argiles JM, Olivan M, Busquets S, et al. Optimal management of cancer anorexia-
10
11 cachexia syndrome. *Cancer Management and Research* 2010;**2**:27-38.
12
- 13 13. Nicolini A, Ferrari P, Masoni MC, et al. Malnutrition, anorexia and cachexia in cancer
14
15 patients: A mini-review on pathogenesis and treatment. *Biomed Pharmacother*
16
17 2013;**67**:807-17.
18
- 19 14. Lawsin C, DuHamel K, Itzkowitz SH, et al. Demographic, medical, and psychosocial
20
21 correlates to CAM use among survivors of colorectal cancer. *Support Care Cancer*
22
23 2007;**15**:557-64.
24
- 25 15. Matthews AK, Sellergren SA, Huo D, et al. Complementary and alternative medicine use
26
27 among breast cancer survivors. *J Altern Complement Med* 2007;**13**:555-62.
28
- 29 16. Kang S, Min H. Ginseng, the 'Immunity Boost': The Effects of Panax ginseng on Immune
30
31 System. *J Ginseng Res* 2012;**36**:354-68.
32
- 33 17. Shergis JL, Zhang AL, Zhou W, et al. Panax ginseng in randomised controlled trials: a
34
35 systematic review. *Phytother Res* 2013;**27**:949-65.
36
37
- 38 18. Harrold JA, Hughes GM, O'Shiel K, et al. Acute effects of a herb extract formulation and
39
40 inulin fibre on appetite, energy intake and food choice. *Appetite* 2013;**62**:84-90.
41
42
- 43 19. Ren S, Zhang H, Mu Y, et al. Pharmacological effects of Astragaloside IV: a literature
44
45 review. *J Tradit Chin Med* 2013;**33**:413-6.
46
47
- 48 20. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali radix for
49
50 cancer-associated anorexia in patients with advanced cancer. *Integr Cancer Ther*
51
52 2010;**9**:24-31.
53
- 54 21. Lou T, Zhang Z, Xi Z, et al. Berberine inhibits inflammatory response and ameliorates
55
56 insulin resistance in hepatocytes. *Inflammation* 2011;**34**:659-67.
57
58
59
60

- 1
2
3
4 22. Zhang J, Wang P, Ouyang H, et al. Targeting cancer-related inflammation: Chinese herbal
5
6 medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. *PLoS*
7
8 *One* 2013;**8**:e70334.
9
- 10 23. He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora
11
12 pall., a traditional chinese herbal medicine. *Front Pharmacol* 2011;**2**:10.
13
- 14 24. Wang S, Wu X, Tan M, et al. Fighting fire with fire: poisonous Chinese herbal medicine
15
16 for cancer therapy. *J Ethnopharmacol* 2012;**140**:33-45.
17
- 18 25. Lu JJ, Dang YY, Huang M, et al. Anti-cancer properties of terpenoids isolated from
19
20 Rhizoma Curcumae--a review. *J Ethnopharmacol* 2012;**143**:406-11.
21
- 22 26. Chen X, Guo J, Bao J, et al. The Anticancer Properties of Salvia Miltiorrhiza Bunge
23
24 (Danshen): A Systematic Review. *Med Res Rev* Published Online First: 7 October
25
26 2013. doi: 10.1002/med.21304.
27
- 28 27. Takeda H, Muto S, Nakagawa K, et al. Rikkunshito as a ghrelin enhancer. *Methods*
29
30 *Enzymol* 2012;**514**:333-51.
31
- 32 28. Iizuka N, Miyamoto K, Hazama S, et al. Anticachectic effects of Coptidis rhizoma, an
33
34 anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. *Cancer*
35
36 *Lett* 2000;**158**:35-41.
37
- 38 29. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
39
40 studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
41
42 *Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane
43
44 Collaboration. Available from www.cochrane-handbook.org, 2011.
45
46
47
48
49
- 50 30. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
51
52 analyses. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
53
54 *Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane
55
56 Collaboration. Available from www.cochrane-handbook.org, 2011.
57
58
59
60

- 1
2
3
4 31. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
5
6 graphical test. *BMJ* 1997;**315**:629-34.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APPENDICES

Appendix 1. MEDLINE (Pubmed) search strategy

#1. exp Neoplasms/

#2. (cancer or oncolog* or neoplasm* or malignan* or tumor or tumour or carcinoma* or adenocarcinoma* or osteosarcoma* or sarcoma* or leukemi* or lymphoma* or teratoma* or metastat*).mp.

#3. #1 or #2

#4. exp Weight loss/

#5. exp Malnutrition/

#6. (cachexia* or cachectic* or weight loss or loss of weight or underweight or malnutrition or wasting syndrome or anorexia* or muscle atrophy or sarcopenia).mp.

#7. or/#4-#6

#8. exp Medicine, East Asian Traditional/

#9. exp Drugs, Chinese herbal/

#10. exp Herbal Medicine/

#11. exp Plants, Medicinal/

#12. (traditional Korean medicine or traditional Chinese medicine or Traditional oriental medicine or Kampo medicine or alternative medicine or complementary medicine or herb or herbal or herbs or decoction* or botanic*).mp.

#13. or/#8-#12

#14. exp Randomized Controlled Trials as Topic/

#15. exp Clinical Trials as Topic/

#16. exp controlled clinical trials as topic/

#17. (randomized controlled trial* or controlled clinical trial* or randomized* or randomly* or placebo or clinical trial* or controlled trial*).mp.

1
2
3
4 #18. or/#14 - #17
5

6 #19. #3 and #7 and #13 and #18
7
8
9

10
11 *Appendix 2. CNKI search strategy*

12
13 (恶病质 or 恶液质 or 癌症恶病质 or 癌恶病质 or 肿瘤恶病质 or 癌性恶病质) and
14

15
16 (中医药 or 中医 or 中西医结合 or 中药 or 中草药 or 中药制剂 or 汤 or 丸 or 散
17

18
19 or 注射液 or 口服液 or 中成药 or 饮) and (随机 or 对照)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Herbal medicines for cancer cachexia : Protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005016.R1
Article Type:	Protocol
Date Submitted by the Author:	10-May-2014
Complete List of Authors:	Park, Bongki; Korea Institute of Oriental Medicine, Medical Research Division Jun, Ji Hee; Korea Institute of Oriental Medicine, Medical Research Division Jung, Jeeyoun; Korea Institute of Oriental Medicine, Medical Research Division You, Sooseong; Korea Institute of Oriental Medicine, Medical Research Division Lee, Myeong Soo; Korea Institute of Oriental Medicine, Medical Research Division
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine, Oncology
Keywords:	COMPLEMENTARY MEDICINE, Adult oncology < ONCOLOGY, Herbal medicine < THERAPEUTICS

SCHOLARONE™
Manuscripts

Only

1
2
3
4
5
6
7
8
9

Herbal medicines for cancer cachexia : Protocol for a systematic review

10
11
12
13
14
15
16
17
18
19

Bongki Park, Ji Hee Jun, Jeeyoun Jung, Sooseong You, Myeong Soo Lee

Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Running title: Protocol of systematic review of herbal medicine for cancer cachexia

***Correspondence to:**

Myeong Soo Lee, PhD

Medical Research Division,

Korea Institute of Oriental Medicine,

Daejeon, 305-811, South Korea

Tel: 82-(0)42-868-9266

Fax: 82-(0)42-868-9622

E-mail: drmslee@gmail.com

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Park BK: sanisapa@kiom.re.kr

Jun JH: zhixi04@kiom.re.kr

Jung JY: jjy0918@kiom.re.kr

You SS: ethink33@kiom.re.kr

Lee MS: drmslee@gmail.com

1
2
3
4 License statement
5

6 *The Corresponding Author has the right to grant on behalf of all authors and does grant on*
7 *behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a*
8 *worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if*
9 *accepted) to be published in BMJ Open and any other BMJ PGL products to exploit all*
10 *subsidiary rights, as set out in our licence ([http://group.bmj.com/products/journals/](http://group.bmj.com/products/journals/instructions-for-authors/licence-forms)*
11 *instructions-for-authors/licence-forms).*
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: To assess the efficacy of herbal medicines as a treatment of cancer cachexia.

Methods and analysis: We will search the following thirteen electronic databases from their inception. MEDLINE (PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Allied and Complementary Medicine Database (AMED), China National Knowledge Infrastructure (CNKI), Wanfang, Journal Integration Platform (VIP) and six Korean Medical Databases (Korean Studies Information, DBPIA, Korea Institute of Science Technology Information, Research Information Center for Health Database, Korean Medline, and National Assembly Library) without restrictions on time or language. The data will be extracted independently by two authors using pre-defined criteria. Disagreements will be resolved by discussion between the authors. The risk of bias will be assessed using the Cochrane of risk of bias tool.

Dissemination: The review will be published in a journal. The review will also be disseminated electronically and in print. An update of the review will be conducted to inform and guide healthcare practice and policy.

Trial registration number: PROSPERO 2013:CRD42013006612

Keywords: Cancer, cachexia, herbal medicine, traditional East Asian medicine, randomised clinical trials, systematic review

Article focus

- *This systematic review aims to evaluate randomized controlled trials and quasi-randomised trials and to present the efficacy of herbal medicines for cancer cachexia.*

Key messages

- *This systematic review will be performed with a comprehensive search strategy and will establish the current state of the evidence using unbiased methods.*

Strengths and limitations of this study

- *The strength of this review is its extensive, unbiased search of various databases without language restriction.*
- *The trial screening and data extraction will be conducted independently by two authors.*
- *The review team consists of experts from each field: traditional Korean medicine (Park BK, Jung JY), traditional Chinese medicine (Jun JH), conventional medicine (You SS) and methodology (Lee MS).*

Introduction

Description of the condition

Cancer cachexia is a common syndrome among cancer patients, especially in advanced cancer. More than 70~80% of advanced cancer patients suffer from cachexia.¹

Generally, cachexia is characterised by loss of weight, muscle atrophy, anorexia and fatigue.

The definition of cancer cachexia differs slightly according to the research study,²⁻⁵ but the recent international consensus has defined cancer cachexia as a multifactorial syndrome characterised by ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.⁴ The pathophysiology of cancer cachexia is a negative energy balance caused by a variable combination of reduced food intake and abnormal metabolism.^{4 6} The metabolic mechanisms of adipose mass reduction, loss of skeletal muscle and protein degradation are known to be mediated by pro-inflammatory cytokines, neuropeptides, hormones, catabolic factors and digestive factors.^{1 6-8}

Cancer cachexia causes numerous clinical problems. Cancer cachexia reduces activity or quality of life⁹ and restricts conventional therapy such as chemotherapy.¹⁰ Above all, Cancer cachexia is associated with a poor survival rate.^{11 12} In various cancer types, the survival of patients with cachexia is shorter than that of other patients.¹

Description of the intervention

There are several agents for managing cancer cachexia. Megestrol acetate, cannabinoids, corticosteroids and ghrelin are known to affect appetite. EPA, HMB, thalidomide, corticosteroids and non-steroidal anti-inflammatory drugs are known to affect cachectic mediators or signal pathways.^{1 6 13} Some drugs, such as megestrol acetate and corticosteroids exhibit confirmed effectiveness in combatting cancer cachexia by randomised controlled

1
2
3
4 trials and systematic reviews.¹ However, to date, there is no identified standard treatment for
5
6 cancer cachexia.
7

8 Herbal medicines have been used widely to treat diverse diseases for thousands of years.
9
10 Especially in East Asia, herbal medicines have been developed on a basis of unique theories:
11
12 Yin and Yang, the five elements and visceral manifestation theory. The major principle of
13
14 treating diseases is reinforcing the healthy qi and eliminating the pathogenic factors. Many
15
16 herbal medicines are prescribed according to this principle.
17

18
19 Recently, herbal medicines have been used to alleviate the adverse effects of conventional
20
21 therapies or to improve a quality of life. A survey demonstrated that 75% of colorectal cancer
22
23 patients used at least one type of complementary alternative medicine (CAM) during their
24
25 lifetimes.¹⁴ Another survey reported that 39% of breast cancer patients used herbs or medical
26
27 herbal teas.¹⁵
28
29

30 31 32 ***How the intervention might work***

33
34 Some herbs, such as ginseng radix, astragali radix or some herbal prescriptions, are known to
35
36 increase appetite, facilitate physical function and boost immune function.¹⁶⁻²⁰ Other herbs,
37
38 such as coptidis rhizoma, exhibit anti-inflammatory functions.²¹⁻²³ Many herbs are associated
39
40 with anti-cancer properties including cancer cell - cytotoxicity, cell-apoptosis and invasion
41
42 and metastasis prevention.²⁴⁻²⁶
43
44

45
46 Many practitioners and researchers have attempted to explore herbal medicines for the
47
48 treatment of cancer cachexia. The oral administration of Rikkunshito is known to stimulate
49
50 ghrelin secretion.²⁷ One research study reported that coptidis rhizoma might exhibit an anti-
51
52 cachectic effect and that berberine, the major component, might prevent cancer-induced
53
54 cachexia.²⁸
55
56
57
58
59
60

Why it is important to do this review

To our knowledge, no systematic reviews assessing herbal medicines in cancer cachexia have been conducted. There is no identified standard treatment for cancer cachexia, and a comprehensive evaluation of the efficacy and the safety of herbal medicines will inform the recommendation for treatment of cancer cachexia.

Objectives

To assess the efficacy of herbal medicines for cancer cachexia.

Methods

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs) and quasi-randomised trials (quasi-RCTs) will be included in this systematic review without restrictions on time or language.

Types of participants

The participants will include cancer patients diagnosed by histological or clinical diagnosis who meet the international consensus of cancer cachexia⁴. The diagnostic criteria for cancer cachexia are as follows :

1. Weight loss > 5% over the past 6 months (in absence of simple starvation); or
2. Body Mass Index (BMI) < 20 and any degree of weight loss > 2%; or
3. Appendicular skeletal muscle index consistent with sarcopenia (males < 7.26 kg/m; females < 5.45 kg/m) and any degree of weight loss > 2%

Types of interventions

1
2
3
4 All types of herbal medicines will be included. There is no limitation on the number of herbs,
5
6 administration methods, dosage or duration of treatment. The comparisons will be either with
7
8 other therapeutic agents such as megestrol acetate or corticosteroids or with no other
9
10 treatment.
11

12 13 14 15 *Types of outcome measures*

16 17 Primary outcomes

- 18 1. Weight gain.
- 19 2. Body composition.

20 21 22 Secondary outcomes

- 23 1. Improvement in quality of life by means of a validated instrument.
- 24 2. Increase of appetite.
- 25 3. Reduction in fatigue.
- 26 4. Serum levels of inflammatory markers, including ESR and CRP as well as TNF-alpha, IL-
27 1, IL-6 and IFN-gamma
- 28 5. Survival rate
- 29 6. Adverse effects.

30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 *Search methods for the identification of studies*

47 48 Electronic searches

49 We will search the following electronic databases regardless of publication date or language:

- 50 ● MEDLINE (PubMed),
- 51 ● The Cochrane Central Register of Controlled Trials (CENTRAL),
- 52 ● EMBASE,

- Allied and Complementary Medicine Database (AMED),
- China National Knowledge Infrastructure (CNKI),
- Wanfang Database.
- VIP (Journal Integration Platform)
- Six Korean Medical Databases (Korean Studies Information, DBPIA, Korea Institute of Science Technology Information, Research Information Center for Health Database, Korean Medline, and National Assembly Library)

Other sources

We will scan the reference lists of reviews and retrieve articles for additional studies. In addition, we will search the WHO International Clinical Trials Registry Platform (ICTRP) (<http://apps.who.int/trialsearch/>) and Google scholar (<http://scholar.google.co.kr/>).

Search strategy

We will model subject strategies for databases on the search strategy designed for MEDLINE (PubMed; see Appendix 1) and CNKI (see Appendix 2) and modify it for use in the other databases.

Data collection and analysis

Selection of studies

Two review authors (Park BK and Jun JH) will independently assess the titles and abstracts of articles searched by electronic databases and determine their eligibility for inclusion. Hard copies of the relevant articles will be retrieved. Disagreements will be resolved by discussion, if necessary, by the arbiter (Lee MS).

Data extraction and management

Two review authors (Park BK and Jun JH) will read all the articles and independently extract the data using a standard data extraction form. The form includes methodology, participants, interventions, duration of treatment, outcomes and conclusions. Consensus will be reached by discussion in the case of discrepancy. When disagreements are not resolved by discussion, they will be arbitrated by another author (Lee MS).

Assessment of the risk of bias in the included studies

Three authors (Park BK, You SS and Jung JY) will assess the risk of bias using the Cochrane tool of risk of bias (version 5.1.0).²⁹ The following items will be assessed: random sequence generation (selection bias), allocation concealment (selection bias), blinding (performance bias and detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other bias. The evaluated domains will be assessed as Yes, No or Unclear according to the criteria. We will resolve any disagreements by discussion or arbitration (Lee MS).

Measurement of the treatment effect

We will use the mean difference (MD) with 95% confidence intervals (CI) for continuous outcomes or risk ratios (RR) or odds ratio (OR) with 95% CI for binary outcomes. If the event rate lower than 1%, Peto Odds ratio (OR) with 95% CI will be used, lower than 20%, OR with 95% CI and more than 20%, RR will be used. In the case of the use of different measurement scales, standardised mean difference (SMD) analysis with 95% CI will be performed.

Units of analysis issues

1
2
3
4 We will include data from parallel-group studies for the meta-analysis. If we include cross-
5
6 over trials, only the first treatment period data will be analysed. When the trial has more than
7
8 one control group, the unit of analysis will be applied to each group.
9

10 11 12 13 *Dealing with missing data*

14
15 We will try to contact the corresponding authors by e-mail if there is any missing or
16
17 insufficient data from the trial as much as possible. The intent-to-treat (ITT) principle will be
18
19 applied for statistical analysis. The individual patient data will be sought from the original
20
21 source or from the published trial reports when the individual patient data are unavailable.
22
23

24 25 26 *Assessment of heterogeneity*

27
28 We will use the random effects model for the meta-analysis. Heterogeneity will be assessed
29
30 by inspecting the forest plots. In addition, heterogeneity will be tested by the I^2 test for
31
32 quantifying inconsistencies among the included studies. A result higher than 50% would
33
34 represent substantial heterogeneity. If heterogeneity exists, we will conduct a subgroup
35
36 analysis to examine the possible cause.³⁰
37
38
39
40
41

42 *Assessment of reporting biases*

43
44 If more than 10 trials are included in the meta-analysis, we will conduct funnel plots to assess
45
46 the potential for publication bias and small study effects.³¹ Asymmetry in funnel plots
47
48 implied possible small study effects, such as publication bias. We will include all eligible
49
50 trials, regardless of their methodological quality.
51
52
53
54

55 *Data synthesis*

56
57 If there are sufficient studies and comparable outcomes, we will perform a meta-analysis
58
59
60

1
2
3
4 using random effect modelling.
5

6 1. Herbal medicine versus conventional medical treatments
7

8 2. Herbal medicine versus no treatment
9

10 3. Herbal medicine versus placebo
11

12 4. Herbal medicine plus conventional medical treatment versus conventional medical
13 treatment only
14
15

16 17 18 19 *Subgroup analysis and investigation of heterogeneity*

20 If there are sufficient data, subgroup analyses will be conducted to explore the differences in
21 the effect sizes, type of cancer, stage of cachexia⁴ and types of herbal medicine.
22
23

24 25 26 27 *Sensitivity analysis*

28 For sensitivity analysis, the meta-analysis will be repeated, substituting decisions
29 alternatively to test the robustness of the primary decisions of the review process. The
30 principal decision nodes are as follows:
31
32

33 1. Methodological quality (sequence generation, allocation concealment or blinding in the
34 assessment of outcomes and symptom severity);
35
36

37 2. Sample size (small sample size studies, e.g., over 30 in each group)
38
39
40
41
42
43
44
45

46 **Ethics and dissemination**

47 Ethical approval is not required, given that this protocol is for a systematic review. The
48 review will be disseminated widely through peer-reviewed publications and conference
49 presentations.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

This is the protocol for a review and there is no primary data collection. The systematic review will be published in a peer-reviewed journal and disseminated electronically or in print. Updates of the review will be conducted to inform and guide healthcare practice and policy.

For peer review only

Funding

The authors were supported by Korea Institute of Oriental Medicine (K13400, K13281).

Contribution of authors

All authors (Park BK, Jun JH, Jung JY, You SS and Lee MS) contributed to the drafting of the protocol. The protocol was revised, and the final version was approved by all authors.

The search strategy was developed and will be run by Park BK and Jun JH. Copies of studies will be obtained by Park BK and Jun JH. Selection of the studies to include will be done by Park BK and Jun JH. Lee MS will act as an arbiter in the study selection stage. Extraction of data from studies will be conducted by Park BK, Jun JH, Jung JY and You SS. Entering data into RevMan will be conducted by Park BK, Jung JY. Carrying out the analysis will be done by Park BK, Jung JY and Lee MS. Interpretation of the analysis will be done by all authors. The final review will be drafted by all authors. The review will be updated by Park BK and Lee MS.

Competing interests

None declared

Data Sharing Statement

No additional data available

References

1. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. *Crit Rev Oncol Hematol* 2013;**88**:625-36.
2. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. *Clin Nutr* 2008;**27**:793-9.
3. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". *Clin Nutr* 2010;**29**:154-9.
4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011;**12**:489-95.
5. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score. Cancer treatment reviews. *Cancer Treat Rev* Published Online First: 28 November 2013. doi: 10.1016/j.ctrv.2013.11.007.
6. Tisdale MJ. Mechanisms of cancer cachexia. *Physiol Rev* 2009;**89**:381-410.
7. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. *Trends Endocrinol Metab* 2013;**24**:174-83.
8. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell Metab* 2012;**16**:153-66.
9. Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. *Lung Cancer* 2003;**40**:295-9.
10. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin Cancer Res* 2009;**15**:2920-6.

- 1
2
3
4 11. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment
5
6 of anorexia-cachexia syndrome. *Cochrane Database Syst Rev* 2013;**3**:CD004310.
7
- 8
9 12. Argiles JM, Olivan M, Busquets S, et al. Optimal management of cancer anorexia-
10
11 cachexia syndrome. *Cancer Management and Research* 2010;**2**:27-38.
12
- 13
14 13. Nicolini A, Ferrari P, Masoni MC, et al. Malnutrition, anorexia and cachexia in cancer
15
16 patients: A mini-review on pathogenesis and treatment. *Biomed Pharmacother*
17
18 2013;**67**:807-17.
19
- 20
21 14. Lawsin C, DuHamel K, Itzkowitz SH, et al. Demographic, medical, and psychosocial
22
23 correlates to CAM use among survivors of colorectal cancer. *Support Care Cancer*
24
25 2007;**15**:557-64.
26
- 27
28 15. Matthews AK, Sellergren SA, Huo D, et al. Complementary and alternative medicine use
29
30 among breast cancer survivors. *J Altern Complement Med* 2007;**13**:555-62.
31
- 32
33 16. Kang S, Min H. Ginseng, the 'Immunity Boost': The Effects of Panax ginseng on Immune
34
35 System. *J Ginseng Res* 2012;**36**:354-68.
36
- 37
38 17. Shergis JL, Zhang AL, Zhou W, et al. Panax ginseng in randomised controlled trials: a
39
40 systematic review. *Phytother Res* 2013;**27**:949-65.
41
- 42
43 18. Harrold JA, Hughes GM, O'Shiel K, et al. Acute effects of a herb extract formulation and
44
45 inulin fibre on appetite, energy intake and food choice. *Appetite* 2013;**62**:84-90.
46
- 47
48 19. Ren S, Zhang H, Mu Y, et al. Pharmacological effects of Astragaloside IV: a literature
49
50 review. *J Tradit Chin Med* 2013;**33**:413-6.
51
- 52
53 20. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali radix for
54
55 cancer-associated anorexia in patients with advanced cancer. *Integr Cancer Ther*
56
57 2010;**9**:24-31.
58
- 59
60 21. Lou T, Zhang Z, Xi Z, et al. Berberine inhibits inflammatory response and ameliorates
insulin resistance in hepatocytes. *Inflammation* 2011;**34**:659-67.

- 1
2
3
4 22. Zhang J, Wang P, Ouyang H, et al. Targeting cancer-related inflammation: Chinese herbal
5
6 medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. *PLoS*
7
8 *One* 2013;**8**:e70334.
9
- 10 23. He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora
11
12 pall., a traditional chinese herbal medicine. *Front Pharmacol* 2011;**2**:10.
13
- 14 24. Wang S, Wu X, Tan M, et al. Fighting fire with fire: poisonous Chinese herbal medicine
15
16 for cancer therapy. *J Ethnopharmacol* 2012;**140**:33-45.
17
- 18 25. Lu JJ, Dang YY, Huang M, et al. Anti-cancer properties of terpenoids isolated from
19
20 Rhizoma Curcumae--a review. *J Ethnopharmacol* 2012;**143**:406-11.
21
- 22 26. Chen X, Guo J, Bao J, et al. The Anticancer Properties of Salvia Miltiorrhiza Bunge
23
24 (Danshen): A Systematic Review. *Med Res Rev* Published Online First: 7 October
25
26 2013. doi: 10.1002/med.21304.
27
- 28 27. Takeda H, Muto S, Nakagawa K, et al. Rikkunshito as a ghrelin enhancer. *Methods*
29
30 *Enzymol* 2012;**514**:333-51.
31
- 32 28. Iizuka N, Miyamoto K, Hazama S, et al. Anticachectic effects of Coptidis rhizoma, an
33
34 anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. *Cancer*
35
36 *Lett* 2000;**158**:35-41.
37
- 38 29. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
39
40 studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
41
42 *Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane
43
44 Collaboration. Available from www.cochrane-handbook.org, 2011.
45
46
47
48
- 49 30. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
50
51 analyses. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
52
53 *Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane
54
55 Collaboration. Available from www.cochrane-handbook.org, 2011.
56
57
58
59
60

- 1
2
3
4 31. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
5
6 graphical test. *BMJ* 1997;**315**:629-34.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9

Herbal medicines for cancer cachexia : Protocol for a systematic review

10 Bongki Park, Ji Hee Jun, Jeeyoun Jung, Sooseong You, Myeong Soo Lee

11
12
13 *Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea*

14
15
16
17 Running title: Protocol of systematic review of herbal medicine for cancer cachexia

18
19
20 ***Correspondence to:**

21 Myeong Soo Lee, PhD

22 Medical Research Division,

23 Korea Institute of Oriental Medicine,

24 Daejeon, 305-811, South Korea

25 Tel: 82-(0)42-868-9266

26 Fax: 82-(0)42-868-9622

27 E-mail: drmslee@gmail.com

28
29
30
31
32
33
34
35 Park BK: sanisapa@kiom.re.kr

36 Jun JH: zhixi04@kiom.re.kr

37 Jung JY: jjy0918@kiom.re.kr

38 You SS: ethink33@kiom.re.kr

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Lee MS: drmslee@gmail.com

1
2
3
4 License statement

5
6 *The Corresponding Author has the right to grant on behalf of all authors and does grant on*
7
8 *behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a*
9
10 *worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if*
11
12 *accepted) to be published in BMJ Open and any other BMJPGJ products to exploit all*
13
14 *subsidiary rights, as set out in our licence ([http://group.bmj.com/products/journals/](http://group.bmj.com/products/journals/instructions-for-authors/licence-forms)*
15 *instructions-for-authors/licence-forms).*
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus

- *This systematic review aims to evaluate randomized controlled trials and quasi-randomised trials and to present the efficacy of herbal medicines for cancer cachexia.*

Key messages

- *This systematic review will be performed with a comprehensive search strategy and will establish the current state of the evidence using unbiased methods.*

Strengths and limitations of this study

- *The strength of this review is its extensive, unbiased search of various databases without language restriction.*
- *The trial screening and data extraction will be conducted independently by two authors.*
- *The review team consists of experts from each field: traditional Korean medicine (Park BK, Jung JY), traditional Chinese medicine (Jun JH), conventional medicine (You SS) and methodology (Lee MS).*

Abstract

Introduction: To assess the efficacy of herbal medicines as a treatment of cancer cachexia.

Methods and analysis: We will search the following thirteen electronic databases from their inception. MEDLINE (PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Allied and Complementary Medicine Database (AMED), China National Knowledge Infrastructure (CNKI), Wanfang, Journal Integration Platform (VIP) and six Korean Medical Databases (Korean Studies Information, DBPIA, Korea Institute of Science Technology Information, Research Information Center for Health Database, Korean Medline, and National Assembly Library) without restrictions on time or language. The data will be extracted independently by two authors using pre-defined criteria. Disagreements will be resolved by discussion between the authors. The risk of bias will be assessed using the Cochrane of risk of bias tool.

Dissemination: The review will be published in a journal. The review will also be disseminated electronically and in print. An updated^d of the review will be conducted to inform and guide healthcare practice and policy.

Trial registration number: PROSPERO 2013:CRD42013006612

Keywords: Cancer, cachexia, herbal medicine, traditional East Asian medicine, randomised clinical trials, systematic review

Introduction

Description of the condition

Cancer cachexia is a common syndrome among cancer patients, especially in advanced cancer. More than 70~80% of advanced cancer patients suffer from cachexia.¹

Generally, cachexia is characterised by loss of weight, muscle atrophy, anorexia and fatigue.

The definition of cancer cachexia differs slightly according to the research study,²⁻⁵ but the recent international consensus has defined cancer cachexia as a multifactorial syndrome characterised by ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.⁴ The pathophysiology of cancer cachexia is a negative energy balance caused by a variable combination of reduced food intake and abnormal metabolism.^{4 6} The metabolic mechanisms of adipose mass reduction, loss of skeletal muscle and protein degradation are known to be mediated by pro-inflammatory cytokines, neuropeptides, hormones, catabolic factors and digestive factors.^{1 6-8}

Cancer cachexia causes numerous clinical problems. Cancer cachexia reduces activity or quality of life⁹ and restricts conventional therapy such as chemotherapy.¹⁰ Above all, Cancer cachexia is associated with a poor survival rate.^{11 12} In various cancer types, the survival of patients with cachexia is shorter than that of other patients.¹

Description of the intervention

There are several agents for managing cancer cachexia. Megestrol acetate, cannabinoids, corticosteroids and ghrelin are known to affect appetite. EPA, HMB, thalidomide, corticosteroids and non-steroidal anti-inflammatory drugs are known to affect cachectic mediators or signal pathways.^{1 6 13} Some drugs, such as megestrol acetate and corticosteroids exhibit confirmed effectiveness in combatting cancer cachexia by randomised controlled

1
2
3
4 trials and systematic reviews.¹ However, to date, there is no identified standard treatment for
5
6 cancer cachexia.

7
8 Herbal medicines have been used widely to treat diverse diseases for thousands of years.
9
10 Especially in East Asia, herbal medicines have been developed on a basis of unique theories:
11
12 Yin and Yang, the five elements and visceral manifestation theory. The major principle of
13
14 treating diseases is reinforcing the healthy qi and eliminating the pathogenic factors. Many
15
16 herbal medicines are prescribed according to this principle.
17

18
19 Recently, herbal medicines have been used to alleviate the adverse effects of conventional
20
21 therapies or to improve a quality of life. A survey demonstrated that 75% of colorectal cancer
22
23 patients used at least one type of complementary alternative medicine (CAM) during their
24
25 lifetimes.¹⁴ Another survey reported that 39% of breast cancer patients used herbs or medical
26
27 herbal teas.¹⁵
28
29

30 31 32 ***How the intervention might work***

33
34 Some herbs, such as ginseng radix, astragali radix or some herbal prescriptions, are known to
35
36 increase appetite, facilitate physical function and boost immune function.¹⁶⁻²⁰ Other herbs,
37
38 such as coptidis rhizoma, exhibit anti-inflammatory functions.²¹⁻²³ Many herbs are associated
39
40 with anti-cancer properties including cancer cell - cytotoxicity, cell-apoptosis and invasion
41
42 and metastasis prevention.²⁴⁻²⁶
43
44

45
46 Many practitioners and researchers have attempted to explore herbal medicines for the
47
48 treatment of cancer cachexia. The oral administration of Rikkunshito is known to stimulate
49
50 ghrelin secretion.²⁷ One research study reported that coptidis rhizoma might exhibit an anti-
51
52 cachectic effect and that berberine, the major component, might prevent cancer-induced
53
54 cachexia.²⁸
55
56
57
58
59
60

Why it is important to do this review

To our knowledge, no systematic reviews assessing herbal medicines in cancer cachexia have been conducted. There is no identified standard treatment for cancer cachexia, and a comprehensive evaluation of the efficacy and the safety of herbal medicines will inform the recommendation for treatment of cancer cachexia.

Objectives

To assess the efficacy of herbal medicines for cancer cachexia.

Methods

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs) and quasi-randomised trials (quasi-RCTs) will be included in this systematic review without restrictions on time or language.

Types of participants

The participants will include cancer patients diagnosed by histological or clinical diagnosis who meet the international consensus of cancer cachexia⁴. The diagnostic criteria for cancer cachexia are as follows :

1. Weight loss > 5% over the past 6 months (in absence of simple starvation); or
2. Body Mass Index (BMI) < 20 and any degree of weight loss > 2%; or
3. Appendicular skeletal muscle index consistent with sarcopenia (males<7.26 kg/m; females<5.45 kg/m) and any degree of weight loss >2%

Types of interventions

1
2
3
4 All types of herbal medicines will be included. There is no limitation on the number of herbs,
5
6 administration methods, dosage or duration of treatment. The comparisons will be either with
7
8 other therapeutic agents such as megestrol acetate or corticosteroids or with no other
9
10 treatment.
11

12 13 14 15 *Types of outcome measures*

16 17 Primary outcomes

- 18 1. Weight gain.
- 19 2. Body composition.

20 21 22 Secondary outcomes

- 23 1. Improvement in quality of life by means of a validated instrument.
- 24 2. Increase of appetite.
- 25 3. Reduction in fatigue.
- 26 4. Serum levels of inflammatory markers, including ESR and CRP as well as TNF-alpha, IL-
27
28 1, IL-6, and IFN-gamma.

29 30 31 32 33 34 35 36 37 5. Survival rate

- 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

46 47 *Search methods for the identification of studies*

48 49 Electronic searches

50 We will search the following electronic databases regardless of publication date or language:

- 51 ● MEDLINE (PubMed),
- 52
- 53 ● The Cochrane Central Register of Controlled Trials (CENTRAL),
- 54
- 55 ● EMBASE,
- 56
- 57
- 58
- 59
- 60

- Allied and Complementary Medicine Database (AMED),
- China National Knowledge Infrastructure (CNKI),
- Wanfang Database.
- VIP (Journal Integration Platform)
- Six Korean Medical Databases (Korean Studies Information, DBPIA, Korea Institute of Science Technology Information, Research Information Center for Health Database, Korean Medline, and National Assembly Library)

Other sources

We will scan the reference lists of reviews and retrieve articles for additional studies. In addition, we will search the WHO International Clinical Trials Registry Platform (ICTRP) (<http://apps.who.int/trialsearch/>), ~~the metaRegister of Controlled Trials (mRCT)~~ (www.controlled-trials.com/mrct), ~~clinical-trials.gov~~ (www.Clinicaltrials.gov) and Google scholar (<http://scholar.google.co.kr/>).

Search strategy

We will model subject strategies for databases on the search strategy designed for MEDLINE (PubMed; see Appendix 1) and CNKI (see Appendix 2) and modify it for use in the other databases.

Data collection and analysis

Selection of studies

Two review authors (Park BK and Jun JH) will independently assess the titles and abstracts of articles searched by electronic databases and determine their eligibility for inclusion. Hard copies of the relevant articles will be retrieved. Disagreements will be resolved by discussion,

1
2
3
4 if necessary, by the arbiter (Lee MS).
5
6
7

8 *Data extraction and management* 9

10 Two review authors (Park BK and Jun JH) will read all the articles and independently extract
11 the data using a standard data extraction form. The form includes methodology, participants,
12 interventions, duration of treatment, outcomes and conclusions. Consensus will be reached by
13 discussion in the case of discrepancy. When disagreements are not resolved by discussion,
14 they will be arbitrated by another author (Lee MS).
15
16
17
18
19
20
21
22
23

24 *Assessment of the risk of bias in the included studies* 25

26 Three authors (Park BK, You SS and Jung JY) will assess the risk of bias using the Cochrane
27 tool of risk of bias (version 5.1.0).²⁹ The following items will be assessed: random sequence
28 generation (selection bias), allocation concealment (selection bias), blinding (performance
29 bias and detection bias), incomplete outcome data (attrition bias), selective outcome reporting
30 (reporting bias) and other bias. The evaluated domains will be assessed as Yes, No or Unclear
31 according to the criteria. We will resolve any disagreements by discussion or arbitration (Lee
32 MS).
33
34
35
36
37
38
39
40
41
42
43

44 *Measurement of the treatment effect* 45

46 We will use the mean difference (MD) with 95% confidence intervals (CI) for continuous
47 outcomes or risk ratios (RR) or odds ratios (OR) with 95% CI for binary outcomes. If the
48 event rate lower than 1%, Peto odds ratio (OR) with 95% CI will be used, lower than 20%,
49 OR with 95% CI and more than 20%, RR will be used. In the case of the use of different
50 measurement scales, standardised mean difference (SMD) analysis with 95% CI will be
51 performed.
52
53
54
55
56
57
58
59
60

Units of analysis issues

We will include data from parallel-group studies for the meta-analysis. If we include cross-over trials, only the first treatment period data will be analysed. When the trial has more than one control group, the unit of analysis will be applied to each group.

Dealing with missing data

We will try to contact the corresponding authors by e-mail if there is any missing or insufficient data from the trial as much as possible. The intent-to-treat (ITT) principle will be applied for statistical analysis. The individual patient data will be sought from the original source or from the published trial reports when the individual patient data are unavailable.

Assessment of heterogeneity

We will use the random effects model for the meta-analysis. Heterogeneity will be assessed by inspecting the forest plots. In addition, heterogeneity will be tested by the I^2 test for quantifying inconsistencies among the included studies. A result higher than 50% would represent substantial heterogeneity. If heterogeneity exists, we will conduct a subgroup analysis to examine the possible cause.³⁰

Assessment of reporting biases

If more than 10 trials are included in the meta-analysis, we will conduct funnel plots to assess the potential for publication bias and small study effects.³¹ Asymmetry in funnel plots implied possible small study effects, such as publication bias. We will include all eligible trials, regardless of their methodological quality.

Data synthesis

If there are sufficient studies and comparable outcomes, we will perform a meta-analysis using random effect modelling.

1. Herbal medicine versus conventional medical treatments
2. Herbal medicine versus no treatment
3. Herbal medicine versus placebo
4. Herbal medicine plus conventional medical treatment versus conventional medical treatment only

Subgroup analysis and investigation of heterogeneity

If there are sufficient data, subgroup analyses will be conducted to explore the differences in the effect sizes, type of cancer, stage of cachexia⁴ and types of herbal medicine.

Sensitivity analysis

For sensitivity analysis, the meta-analysis will be repeated, substituting decisions alternatively to test the robustness of the primary decisions of the review process. The principal decision nodes are as follows:

1. Methodological quality (sequence generation, allocation concealment or blinding in the assessment of outcomes and symptom severity);
2. Sample size (small sample size studies, e.g., over 30 in each group)

Ethics and dissemination

Ethical approval is not required, given that this protocol is for a systematic review. The review will be disseminated widely through peer-reviewed publications and conference presentations.

Discussion

This is the protocol for a review and there is no primary data collection. The systematic review will be published in a peer-reviewed journal and disseminated electronically or in print. [Update of the review will be conducted to inform and guide healthcare practice and policy.](#)

For peer review only

Contribution of authors

All authors (Park BK, Jun JH, Jung JY, You SS and Lee MS) contributed to the drafting of the protocol. The protocol was revised, and the final version was approved by all authors. The search strategy was developed and will be run by Park BK and Jun JH. Copies of studies will be obtained by Park BK and Jun JH. Selection of the studies to include will be done by Park BK and Jun JH. Lee MS will act as an arbiter in the study selection stage. Extraction of data from studies will be conducted by Park BK, Jun JH, Jung JY and You SS. Entering data into RevMan will be conducted by Park BK, Jung JY. Carrying out the analysis will be done by Park BK, Jung JY and Lee MS. Interpretation of the analysis will be done by all authors. The final review will be drafted by all authors. The review will be updated by Park BK and Lee MS.

Competing interests

None declared

Funding

The authors were supported by Korea Institute of Oriental Medicine (K13400, K13281).

References

1. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. *Crit Rev Oncol Hematol* 2013;**88**:625-36.
2. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. *Clin Nutr* 2008;**27**:793-9.
3. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". *Clin Nutr* 2010;**29**:154-9.
4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011;**12**:489-95.
5. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score. Cancer treatment reviews. *Cancer Treat Rev* Published Online First: 28 November 2013. doi: 10.1016/j.ctrv.2013.11.007.
6. Tisdale MJ. Mechanisms of cancer cachexia. *Physiol Rev* 2009;**89**:381-410.
7. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. *Trends Endocrinol Metab* 2013;**24**:174-83.
8. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. *Cell Metab* 2012;**16**:153-66.
9. Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. *Lung Cancer* 2003;**40**:295-9.
10. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin Cancer Res* 2009;**15**:2920-6.

- 1
2
3
4 11. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment
5
6 of anorexia-cachexia syndrome. *Cochrane Database Syst Rev* 2013;**3**:CD004310.
7
- 8
9 12. Argiles JM, Olivan M, Busquets S, et al. Optimal management of cancer anorexia-
10
11 cachexia syndrome. *Cancer Management and Research* 2010;**2**:27-38.
12
- 13 13. Nicolini A, Ferrari P, Masoni MC, et al. Malnutrition, anorexia and cachexia in cancer
14
15 patients: A mini-review on pathogenesis and treatment. *Biomed Pharmacother*
16
17 2013;**67**:807-17.
18
- 19 14. Lawsin C, DuHamel K, Itzkowitz SH, et al. Demographic, medical, and psychosocial
20
21 correlates to CAM use among survivors of colorectal cancer. *Support Care Cancer*
22
23 2007;**15**:557-64.
24
- 25 15. Matthews AK, Sellergren SA, Huo D, et al. Complementary and alternative medicine use
26
27 among breast cancer survivors. *J Altern Complement Med* 2007;**13**:555-62.
28
- 29 16. Kang S, Min H. Ginseng, the 'Immunity Boost': The Effects of Panax ginseng on Immune
30
31 System. *J Ginseng Res* 2012;**36**:354-68.
32
- 33 17. Shergis JL, Zhang AL, Zhou W, et al. Panax ginseng in randomised controlled trials: a
34
35 systematic review. *Phytother Res* 2013;**27**:949-65.
36
37
- 38 18. Harrold JA, Hughes GM, O'Shiel K, et al. Acute effects of a herb extract formulation and
39
40 inulin fibre on appetite, energy intake and food choice. *Appetite* 2013;**62**:84-90.
41
42
- 43 19. Ren S, Zhang H, Mu Y, et al. Pharmacological effects of Astragaloside IV: a literature
44
45 review. *J Tradit Chin Med* 2013;**33**:413-6.
46
47
- 48 20. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali radix for
49
50 cancer-associated anorexia in patients with advanced cancer. *Integr Cancer Ther*
51
52 2010;**9**:24-31.
53
- 54 21. Lou T, Zhang Z, Xi Z, et al. Berberine inhibits inflammatory response and ameliorates
55
56 insulin resistance in hepatocytes. *Inflammation* 2011;**34**:659-67.
57
58
59
60

- 1
2
3
4 22. Zhang J, Wang P, Ouyang H, et al. Targeting cancer-related inflammation: Chinese herbal
5
6 medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. *PLoS*
7
8 *One* 2013;**8**:e70334.
9
- 10 23. He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora
11
12 pall., a traditional chinese herbal medicine. *Front Pharmacol* 2011;**2**:10.
13
- 14 24. Wang S, Wu X, Tan M, et al. Fighting fire with fire: poisonous Chinese herbal medicine
15
16 for cancer therapy. *J Ethnopharmacol* 2012;**140**:33-45.
17
- 18 25. Lu JJ, Dang YY, Huang M, et al. Anti-cancer properties of terpenoids isolated from
19
20 Rhizoma Curcumae--a review. *J Ethnopharmacol* 2012;**143**:406-11.
21
- 22 26. Chen X, Guo J, Bao J, et al. The Anticancer Properties of Salvia Miltiorrhiza Bunge
23
24 (Danshen): A Systematic Review. *Med Res Rev* Published Online First: 7 October
25
26 2013. doi: 10.1002/med.21304.
27
- 28 27. Takeda H, Muto S, Nakagawa K, et al. Rikkunshito as a ghrelin enhancer. *Methods*
29
30 *Enzymol* 2012;**514**:333-51.
31
- 32 28. Iizuka N, Miyamoto K, Hazama S, et al. Anticachectic effects of Coptidis rhizoma, an
33
34 anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. *Cancer*
35
36 *Lett* 2000;**158**:35-41.
37
- 38 29. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
39
40 studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
41
42 *Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane
43
44 Collaboration. Available from www.cochrane-handbook.org, 2011.
45
46
47
48
49
- 50 30. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
51
52 analyses. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
53
54 *Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane
55
56 Collaboration. Available from www.cochrane-handbook.org, 2011.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

31. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629-34.

For peer review only

APPENDICES

Appendix 1. MEDLINE (Pubmed) search strategy

#1. exp Neoplasms/

#2. (cancer or oncolog* or neoplasm* or malignan* or tumor or tumour or carcinoma* or adenocarcinoma* or osteosarcoma* or sarcoma* or leukemi* or lymphoma* or teratoma* or metastat*).mp.

#3. #1 or #2

#4. exp Weight loss/

#5. exp Malnutrition/

#6. (cachexia* or cachectic* or weight loss or loss of weight or underweight or malnutrition or wasting syndrome or anorexia* or muscle atrophy or sarcopenia).mp.

#7. or/#4-#6

#8. exp Medicine, East Asian Traditional/

#9. exp Drugs, Chinese herbal/

#10. exp Herbal Medicine/

#11. exp Plants, Medicinal/

#12. (traditional Korean medicine or traditional Chinese medicine or Traditional oriental medicine or Kampo medicine or alternative medicine or complementary medicine or herb or herbal or herbs or decoction* or botanic*).mp.

#13. or/#8-#12

#14. exp Randomized Controlled Trials as Topic/

#15. exp Clinical Trials as Topic/

#16. exp controlled clinical trials as topic/

#17. (randomized controlled trial* or controlled clinical trial* or randomized* or randomly* or placebo or clinical trial* or controlled trial*).mp.

1
2
3
4 #18. or/#14 - #17
5

6 #19. #3 and #7 and #13 and #18
7
8
9

10
11 *Appendix 2. CNKI search strategy*

12
13 (恶病质 or 恶液质 or 癌症恶病质 or 癌恶病质 or 肿瘤恶病质 or 癌性恶病质) and

14
15
16 (中医药 or 中医 or 中西医结合 or 汉方 or 汉方医学 or 东洋医学 or 中药 or 中草

17
18
19 药 or 中药制剂 or 汤 or 丸 or 散 or 注射液 or 口服液 or 中成药 or 饮) and (随机

20
21
22
23 or 对照)
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APPENDICES

Appendix 1. MEDLINE (Pubmed) search strategy

#1. exp Neoplasms/

#2. (cancer or oncolog* or neoplasm* or malignan* or tumor or tumour or carcinoma* or adenocarcinoma* or osteosarcoma* or sarcoma* or leukemi* or lymphoma* or teratoma* or metastat*).mp.

#3. #1 or #2

#4. exp Weight loss/

#5. exp Malnutrition/

#6. (cachexia* or cachectic* or weight loss or loss of weight or underweight or malnutrition or wasting syndrome or anorexia* or muscle atrophy or sarcopenia).mp.

#7. or/#4-#6

#8. exp Medicine, East Asian Traditional/

#9. exp Drugs, Chinese herbal/

#10. exp Herbal Medicine/

#11. exp Plants, Medicinal/

#12. (traditional Korean medicine or traditional Chinese medicine or Traditional oriental medicine or Kampo medicine or alternative medicine or complementary medicine or herb or herbal or herbs or decoction* or botanic*).mp.

#13. or/#8-#12

#14. exp Randomized Controlled Trials as Topic/

#15. exp Clinical Trials as Topic/

#16. exp controlled clinical trials as topic/

#17. (randomized controlled trial* or controlled clinical trial* or randomized* or randomly* or placebo or clinical trial* or controlled trial*).mp.

1
2
3
4 #18. or/#14 - #17
5
6

7 #19. #3 and #7 and #13 and #18
8
9

10
11 ***Appendix 2. CNKI search strategy***
12

13
14 (恶病质 or 恶液质 or 癌症恶病质 or 癌恶病质 or 肿瘤恶病质 or 癌性恶病质) and (中医
15
16
17
18 药 or 中医 or 中西医结合 or 汉方 or 汉方医学 or 东洋医学 or 中药 or 中草药 or 中药制
19
20
21 剂 or 汤 or 丸 or 散 or 注射液 or 口服液 or 中成药 or 饮) and (随机 or 对照)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60